Elacestrant: Treatment Considerations, Including Dosing and Compliance

This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.

Mardones explores considerations for using oral selective estrogen receptor degraders (SERDs) with Callahan, Vidal, and Gradishar. Callahan highlights patients for whom she wouldn’t consider oral SERDs, emphasizing the need for alternatives in visceral crisis situations. Vidal discusses the recommended dose schedule, dose modifications, and potential adherence concerns, noting the convenience of oral therapy despite adherence challenges. Gradishar emphasizes the continuous and individualized treatment duration, which continues for as long as the patient responds and tolerates the therapy. Callahan sheds light on determining treatment failure, emphasizing the importance of definitive disease progression rather than relying solely on liquid biopsy results. The discussion provides insights into patient selection, dosing considerations, adherence challenges, and duration of treatment with oral SERDs, offering practical guidance for clinicians.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.